SCHEMBL4692187

SCHEMBL4692187

CC(=O)c1cc2cc(NC3=C(c4ccccc4)C(=O)N(Cc4cccnc4)C3=O)ccc2o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.47
NR1H3 Q13133 4/20 0.47
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
POLB P06746 3/20 0.42
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 2/20 0.40
USP2 O75604 1/20 0.40
ESR1 P03372 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NAMPT P43490 2/20 0.39
PTK2B Q14289 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5747436 0.96 NR1H2 (0.44) NR1H2NR1H3PIM1PIM2POLB
SCHEMBL5744486 0.82 NR1H2 (0.37) NR1H2NR1H3POLBTSHRMEN1
SCHEMBL4692190 0.80 NR1H2 (0.45) NR1H2NR1H3TSHRMEN1TP53
SCHEMBL4688047 0.79 NR1H2 (0.76) NR1H2NR1H3POLBMEN1KMT2A
SCHEMBL4688066 0.76 NR1H2 (0.80) NR1H2NR1H3MEN1TP53CYP3A4
SCHEMBL5745530 0.75 NR1H2 (0.78) NR1H2NR1H3MEN1TP53KMT2A
SCHEMBL4692192 0.74 NR1H2 (0.43) NR1H2NR1H3POLBTSHRALDH1A1
SCHEMBL4691823 0.73 NR1H2 (0.56) NR1H2NR1H3PIM1POLBTP53
SCHEMBL4692995 0.72 NR1H2 (0.60) NR1H2NR1H3CYP3A4
SCHEMBL4689233 0.72 NR1H2 (0.60) NR1H2NR1H3CYP3A4KDM4ENAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1646626-B1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2008-07-02 EP claimed
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators ASTRAZENECA AB (SE) 2006-10-19 US claimed
EP-1646626-A1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS AstraZeneca AB (SE) 2006-04-19 EP claimed
WO-2005005417-A1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2005-01-20 WO claimed
US-7432288-B2 Pyrrole-2,5-dione derivatives as Liver X receptor modulators ASTRAZENECA AB (SE) 2008-10-07 US disclosed
EP-1646626-B1 PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2008-07-02 EP disclosed
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators ASTRAZENECA AB (SE) 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235015-A1 Pyrrole-2,5-dione derivatives as liver x receptor modulators NR1H2, NR1H3, SREBF2 NR1H2 1/4885NR1H3 2/4885PIM1 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.